Abstract
Currently, no therapies are available for Zellweger spectrum disorders (ZSDs), a group of genetic metabolic disorders characterised by a deficiency of functional peroxisomes. In a previous study, we showed that oral cholic acid (CA) treatment can suppress bile acid synthesis in ZSD patients and, thereby, decrease plasma levels of toxic C27-bile acid intermediates, one of the biochemical abnormalities in these patients. However, no effect on clinically relevant outcome measures could be observed after 9 months of CA treatment. It was noted that, in patients with advanced liver disease, caution is needed because of possible hepatotoxicity. An extension study of the previously conducted pretest-posttest design study was conducted including 17 patients with a ZSD. All patients received oral CA for an additional period of 12 months, encompassing a total of 21 months of treatment. Multiple clinically relevant parameters and markers for bile acid synthesis were assessed after 15 and 21 months of treatment. Bile acid synthesis was still suppressed after 21 months of CA treatment, accompanied with reduced levels of C27-bile acid intermediates in plasma. These levels significantly increased again after discontinuation of CA. No significa...Continue Reading
References
Feb 1, 1992·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·K D SetchellA Morelli
Jan 1, 1991·Journal of Inherited Metabolic Disease·P T Clayton
Oct 1, 1987·European Journal of Clinical Investigation·J R Van EldereJ M Saudubray
Jun 29, 1999·Journal of Inherited Metabolic Disease·A H BootsmaP Vreken
Feb 2, 2000·Nature Genetics·S FerdinandusseR J Wanders
Jan 4, 2003·Gastroenterology·Kenneth D R SetchellRobert H Squires
Jun 8, 2006·Annual Review of Biochemistry·Ronald J A Wanders, Hans R Waterham
Oct 13, 2006·Biochimica Et Biophysica Acta·Sacha Ferdinandusse, Sander M Houten
Nov 22, 2007·Journal of Pediatric Gastroenterology and Nutrition·Victor de LédinghenThierry Lamireau
Jan 13, 2009·Molecular Genetics and Metabolism·Sacha FerdinandusseRonald J A Wanders
Jan 23, 2010·American Journal of Physiology. Gastrointestinal and Liver Physiology·Tim C M A SchreuderFrank G Schaap
Mar 15, 2012·World Journal of Gastroenterology : WJG·Dorothea HaasJürgen G Okun
Sep 18, 2012·Current Drug Metabolism·Ronald J A Wanders, Sacha Ferdinandusse
Nov 6, 2012·Biochimie·Frank G SchaapIngrid C Gaemers
Jan 5, 2013·Orphanet Journal of Rare Diseases·Kristoffer HaugarvollLaurence A Bindoff
Apr 18, 2013·Obesity·Bart G P KootMarc A Benninga
Jun 26, 2013·Developmental Disabilities Research Reviews·Nancy E BravermanGillian E Maclean
Aug 29, 2013·Nature Reviews. Gastroenterology & Hepatology·Frank G SchaapPeter L M Jansen
Mar 5, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Dewei YeAimin Xu
Mar 29, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Marica Cariello, Antonio Moschetta
Aug 20, 2015·Journal of Inherited Metabolic Disease·Kevin BerendseBwee Tien Poll-The
Dec 3, 2015·Orphanet Journal of Rare Diseases·Femke C C KlouwerBwee Tien Poll-The
Jan 12, 2016·Molecular Genetics and Metabolism·Nancy E BravermanMousumi Bose
Jul 30, 2016·Journal of Inherited Metabolic Disease·Kevin BerendseBwee Tien Poll-The
Sep 7, 2016·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Martin LeníĿekLibor Vítek
Jun 24, 2017·Journal of Pediatric Gastroenterology and Nutrition·James E HeubiKenneth D R Setchell
Sep 28, 2017·Journal of Pediatric Gastroenterology and Nutrition·Femke C C KlouwerBart G P Koot